Swiss pharmaceutical giant Novartis announced Sunday that it will buy San Diego-based Avidity Biosciences in a $12 billion all-cash deal.
Founded in 2012, Avidity is developing a new class of RNA therapeutics called antibody oligonucleotide conjugates to treat genetic neuromuscular diseases such as Duchenne muscular dystrophy.
“Avidity’s pioneering AOC platform for RNA therapeutics and its late-stage assets bolster our commitment to delivering innovative, targeted and potentially first-in-class medicines to treat devastating, progressive neuromuscular diseases,” said Vas Narasimhan, CEO of Novartis.
“The Avidity team has built robust programs with industry-leading delivery of RNA therapeutics to muscle tissue. We look forward to developing these programs to meaningfully change the trajectory of diseases for patients,” Narasimhan said.
Avidity stockholders will receive $72 per share in cash at closing, representing a premium of 46% over the stock’s closing price on Friday.
Novartis recently celebrated 25 years of operations in the San Diego region, and earlier this year announced plans to open a $1.1 billion global research hub here.
Hence then, the article about switzerland s novartis buying san diego biotech avidity in 12 billion cash deal was published today ( ) and is available on Times of San Diego ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Switzerland’s Novartis buying San Diego biotech Avidity in $12 billion cash deal )
Also on site :
- Human heads displayed at Ecuador tourist beach in warning to gangs
- Nazi salutes and drug cartels: Dutch mercenary recounts service with Kiev’s military
- Macy’s Valley Fair shoppers thwart Rolex watch thieves